This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Adatia, I. Articles by Haworth, S. G. Search for Related Content PubMed PubMed Citation Articles by Adatia, I. Articles by Haworth, S. G.

Circulation, Vol 88, 2117-2122, Copyright © 1993 by American Heart Association

ARTICLES

Thromboxane A2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease

I Adatia, SE Barrow, PD Stratton, VM Miall-Allen, JM Ritter and SG Haworth
Developmental Vascular Biology and Pharmacology Unit, United Medical School, Guy's Hospital, London, UK.

BACKGROUND. The pathogenesis of pulmonary vascular disease in children with congenital heart disease is incompletely understood. Thromboxane (TX) A2 and prostacyclin (PGI2) have opposing effects on platelet aggregation and pulmonary vascular smooth muscle. An imbalance in their biosynthesis could contribute to the progressive increase in pulmonary vascular resistance seen in older untreated patients with pulmonary hypertensive congenital heart disease and the thrombotic complications they may develop. METHODS AND RESULTS. We investigated TXA2 and PGI2 biosynthesis in 15 young children (0.2 to 2.25 years old) with congenital heart disease with increased pulmonary blood flow and potentially reversible pulmonary vascular disease by measuring urinary excretion of 2,3-dinor-TXB2 and 2,3-dinor-6-oxoprostaglandin (PG) F1 alpha and compared the findings with those in 16 healthy children (0.5 to 2.8 years old). 2,3-Dinor-TXB2 excretion was greater in the patients than in control subjects (1253 +/- 161 versus 592 +/- 122 ng/g creatinine; P < .001). Excretion of 2,3-dinor-6-oxo-PGF1 alpha was 452 +/- 54 compared with 589 +/- 95 ng/g creatinine in control subjects. In 5 patients who underwent successful cardiac surgery > or = 1 year later excretion of 2,3-dinor-TXB2 decreased from 1100 +/- 298 to 609 +/- 131 ng/g creatinine (P < .05), a value comparable to those in 5 healthy children of similar age (749 +/- 226 ng/g creatinine). We also compared 15 patients (11 to 23 years old) with advanced irreversible pulmonary vascular disease with 19 healthy control subjects (10 to 23 years old). The ratio of TX to PGI2 metabolite excretion was greater in the patients than in control subjects (3.5 +/- 0.6 versus 2.0 +/- 0.3; P < .05). CONCLUSIONS. There is increased 2,3-dinor-TXB2 excretion in children with congenital heart disease and a high pulmonary blood flow that may reflect an imbalance in biosynthesis of TXA2 and PGI2 in the pulmonary vascular bed. The imbalance may contribute to the progressive development of increased pulmonary vascular resistance and persists in older patients whose heart defects are uncorrected.

This article has been cited by other articles:

				M. Kataoka, N. Nagaya, T. Satoh, T. Itoh, S. Murakami, T. Iwase, Y. Miyahara, S. Kyotani, Y. Sakai, K. Kangawa, et al. A Long-Acting Prostacyclin Agonist with Thromboxane Inhibitory Activity for Pulmonary Hypertension Am. J. Respir. Crit. Care Med., December 15, 2005; 172(12): 1575 - 1580. [Abstract] [Full Text] [PDF]

				C.-F. Lam, T. E. Peterson, A. J. Croatt, K. A. Nath, and Z. S. Katusic Functional adaptation and remodeling of pulmonary artery in flow-induced pulmonary hypertension Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2334 - H2341. [Abstract] [Full Text] [PDF]

				C. D. Fike, Y. Zhang, and M. R. Kaplowitz Thromboxane inhibition reduces an early stage of chronic hypoxia-induced pulmonary hypertension in piglets J Appl Physiol, August 1, 2005; 99(2): 670 - 676. [Abstract] [Full Text] [PDF]

				Y. Song, J. E. Jones, H. Beppu, J. F. Keaney Jr, J. Loscalzo, and Y.-Y. Zhang Increased Susceptibility to Pulmonary Hypertension in Heterozygous BMPR2-Mutant Mice Circulation, July 26, 2005; 112(4): 553 - 562. [Abstract] [Full Text] [PDF]

				J. Belik, R. P. Jankov, J. Pan, M. Yi, C. R. Pace-Asciak, and A. K. Tanswell Effect of 8-isoprostaglandin F2{alpha} on the newborn rat pulmonary arterial muscle and endothelium J Appl Physiol, November 1, 2003; 95(5): 1979 - 1985. [Abstract] [Full Text] [PDF]

				C. D. Fike, M. R. Kaplowitz, and S. L. Pfister Arachidonic acid metabolites and an early stage of pulmonary hypertension in chronically hypoxic newborn pigs Am J Physiol Lung Cell Mol Physiol, February 1, 2003; 284(2): L316 - L323. [Abstract] [Full Text] [PDF]

				D. N. Cornfield, E. R. Resnik, J. M. Herron, O. Reinhartz, and J. R. Fineman Pulmonary vascular K+ channel expression and vasoreactivity in a model of congenital heart disease Am J Physiol Lung Cell Mol Physiol, December 1, 2002; 283(6): L1210 - L1219. [Abstract] [Full Text] [PDF]

				C. D. Fike, M. R. Kaplowitz, and M. Bousamra II eNOS and prostanoid enzymes in lungs of newborn piglets with chronic aortopulmonary shunts Am J Physiol Lung Cell Mol Physiol, August 1, 2001; 281(2): L475 - L482. [Abstract] [Full Text] [PDF]

				I. Schulze-Neick, D. J. Penny, M. L. Rigby, C. Morgan, A. Kelleher, P. Collins, J. Li, A. Bush, E. A. Shinebourne, and A. N. Redington L-Arginine and Substance P Reverse the Pulmonary Endothelial Dysfunction Caused by Congenital Heart Surgery Circulation, August 17, 1999; 100(7): 749 - 755. [Abstract] [Full Text] [PDF]